Breaking News Instant updates and real-time market news.

EVHC

Envision Healthcare

$55.36

-2.1 (-3.65%)

, HCA

HCA Holdings

$84.12

-0.49 (-0.58%)

07:32
04/21/17
04/21
07:32
04/21/17
07:32

Jefferies sees risk to Envision's guidance, cuts target to $75

With pre-releases from HCA Holdings (HCA) and MEDNAX (MD) highlighting payor mix challenges, Jefferies analyst Brian Tanquilut sees risk to Envision Healthcare's (EVHC) guidance. Snowstorms in March and payor mix pressure were likely not fully baked into Envision's Q1 outlook, Tanquilut tells investors in a research note. The analyst expects a "modest" Q1 EBITDA miss. He lowered his price target for Envision shares to $75 from $82 but keeps a Buy rating on the name. The stock's significant decline since Feb. 28 already reflects expectations for a miss and guidance cut, the analyst contends.

EVHC

Envision Healthcare

$55.36

-2.1 (-3.65%)

HCA

HCA Holdings

$84.12

-0.49 (-0.58%)

MD

MEDNAX

$61.30

-5.39 (-8.08%)

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 04

    May

  • 06

    Jun

EVHC Envision Healthcare
$55.36

-2.1 (-3.65%)

03/14/17
RBCM
03/14/17
NO CHANGE
RBCM
Envision unit could fetch over $2B after Air Methods deal, says RBC Capital
RBC Capital analyst Frank Morgan believes Envision Healthcare's (EVHC) AMR unit could be worth $2.1B-$2.3B, or $17-$19 per share, after peer Air Methods (AIRM) sold for a 20% premium. Envision said on the Q4 earnings call that it is exploring strategic options for the division. The analyst has an Outperform rating on Envision shares.
03/01/17
RHCO
03/01/17
NO CHANGE
RHCO
Envision Healthcare outlook positive despite 'soft' results, says SunTrust
SunTrust analyst David MacDonald says that Envision reported "soft" Q4 results and provided "soft" 2017 guidance. However, the analyst says that the company's 2017 volumes are on track, while its guidance indicates that its adjusted EBITDA will rise by low double digit percentage levels. The analyst cut his price target on Envision to $85 from $100 but keeps a Buy rating on the stock.
03/01/17
UBSW
03/01/17
NO CHANGE
Target $75
UBSW
Buy
Envision Healthcare price target lowered to $75 from $92 at UBS
UBS analyst A.J. Rice lowered his price target on Envision Healthcare to $75 from $92 following Q4 results. The analyst cited soft Q4 trends, sluggish same store sales volume, and guidance that was below the Street's expectations. Rice maintained his Buy rating on Envision Healthcare shares.
03/01/17
JEFF
03/01/17
NO CHANGE
Target $82
JEFF
Buy
Envision Healthcare guidance miss not a surprise, says Jefferies
Jefferies analyst Brian Tanquilut believes Envision Healthcare's discounted valuation shows that investors have been anticipating a volume-driven FY17 guidance miss for the last few months. Thus, last night's guidance shortfall, while wider than expectations, does not come as a surprise, Tanquilut tells investors in a post-earnings research note. The analyst lowered his price target for Envision shares to $82 from $90 and keeps a Buy rating on the name. He believes the company's fundamentals are intact and the valuation is "compelling."
HCA HCA Holdings
$84.12

-0.49 (-0.58%)

03/27/17
03/27/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Adobe (ADBE) upgraded to Buy from Neutral at BTIG. 2. Best Buy (BBY) upgraded to Overweight from Neutral at Piper Jaffray with analyst Peter Keith saying store closures from hhgregg and potentially Sears (SHLD) could lift Best Buy's comp sales by 2%, Keith tells investors in a research note. Further, the upcoming iPhone and Samsung Galaxy Note launches should bring a "strong smartphone upgrade cycle," the analyst contends. 3. HCA Holdings (HCA) and Universal Health (UHS) were upgraded to Buy from Neutral at Mizuho. 4. Weatherford (WFT) upgraded to Outperform from Market Perform at Wells Fargo with analyst Judson Bailey citing greater confidence in improving operations with the hire of CEO Mark McCollum and the formation of the OneStim joint venture. 5. Brookdale Senior Living (BKD) upgraded to Buy from Hold at Jefferies with analyst Brian Tanquilut citing an improved risk/reward following the recent pullback in the shares. The analyst sees a greater than 50% probability that Brookdale's ongoing sale process results in a deal, but thinks the stock can reach $14.50 even without a takeout. He upped his price target for the shares to $16.50 from $14. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/27/17
MZHO
03/27/17
UPGRADE
Target $98
MZHO
Buy
HCA Holdings upgraded to Buy following ACA repeal failure at Mizuho
As previously reported, Mizuho upgraded HCA Holdings to Buy from Neutral with a $98 price target. Analyst Sheryl Skolnick said the failure of the GOP to move on ACA repeal out of the House, will result in the continuation of the important benefit of Medicaid expansion and without a near-or medium-term threat of block grants. Additionally, the analyst views HCA Holdings as undervalued given strong volumes and free cash flow.
03/27/17
MZHO
03/27/17
UPGRADE
MZHO
Buy
HCA Holdings upgraded to Buy from Neutral at Mizuho
04/04/17
DBAB
04/04/17
INITIATION
DBAB
Buy
HCA Holdings initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Chris Rigg initiated HCA Holdings with a Buy rating and a $103 price target, noting the company's significant market share in some of the fastest growing markets in the U.S., strong free cash flow, and history of returning capital to shareholders.
MD MEDNAX
$61.30

-5.39 (-8.08%)

03/21/17
BARD
03/21/17
DOWNGRADE
Target $72
BARD
Neutral
MEDNAX downgraded to Neutral at Baird
As previously reported, Baird analyst Whit Mayo downgraded MEDNAX to Neutral from Outperform citing a balanced risk/reward, weak organic growth, its sector high historical and relative EBITDA valuation, and a current setup that appears to be reliant on M&A. Mayo maintained his $72 price target on MEDNAX shares.
03/10/17
03/10/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Dollar General (DG) downgraded to Neutral from Buy at Buckingham with the firm's analyst saying the environment has become more difficult since the bullish analyst day last spring. The firm's analyst said shares do not appear to fully factor in sales and margin challenges and sees risk to Street expectations. 2. MEDNAX (MD) downgraded to Neutral from Overweight at JPMorgan with analyst Gary Taylor citing valuation following the recent rally in the shares. The analyst says he can't with confidence bump up his $69 price target given the multi-year slowdown of organic growth and its high Medicaid payor exposure. 3. Loxo Oncology (LOXO) downgraded to Neutral from Buy at Citi with analyst Yigal Nochomovitz saying the stock is now fairly valued. The reflect the equity financing in January which expanded the share count and rising R&D spend, the analyst cut his price target for the shares to $45 from $49. He believes, however, that Loxo management is executing the business plan well. 4. Kimberly-Clark (KMB) downgraded to Hold on competition, valuation at Societe Generale with analyst Iain Simpson saying price competition in the U.S. has picked up as P&G is becoming more aggressive with its mid-tier Luvs and competition in Brazil and China remains "tough." The analyst expects cost cutting to drive margins and views cash returns as "robust," but said valuation has caught up with fundamentals. 5. Ionis Pharmaceuticals (IONS) downgraded to Sell from Neutral at Goldman with analyst Salveen Richter saying Ionis has a "lackluster" track record of developing successful drugs and ongoing toxicity across multiple drugs. If volanesorsen is approved for FCS, Richter expects safety/compliance issues and the launch focus on specialists will result in limited returns, similar to drug Kynamro for high cholesterol. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/21/17
BARD
03/21/17
DOWNGRADE
BARD
Neutral
MEDNAX downgraded to Neutral from Outperform at Baird
03/21/17
03/21/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Sprouts Farmers Market (SFM) downgraded to Market Perform at BMO Capital. 2. HubSpot (HUBS) downgraded to Outperform from Strong Buy at Raymond James analyst Terry Tilman saying shares have significantly outperformed year-to-date and recommends taking some profits. 3. MEDNAX (MD) downgraded to Neutral from Outperform at Baird analyst Whit Mayo citing a balanced risk/reward, weak organic growth, its sector high historical and relative EBITDA valuation, and a current setup that appears to be reliant on M&A. 4. Cracker Barrel (CBRL) downgraded to Hold from Buy at Argus with analyst John Staszak saying he expects customer traffic to remain weak and same-store sales growth to decelerate over the next several quarters. 5. Conagra Brands (CAG), Kellogg (K), J.M. Smucker (SJM), General Mills (GIS), and Campbell Soup (CPB) were downgraded to Underperform from Market Perform at Bernstein. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

15:17
06/28/17
06/28
15:17
06/28/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
06/28/17
06/28
15:16
06/28/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLCO

Melco Resorts & Entertainment

$22.71

-0.29 (-1.26%)

15:10
06/28/17
06/28
15:10
06/28/17
15:10
Options
Melco Resorts with a bullish short-term option play »

Melco Resorts with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:05
06/28/17
06/28
15:05
06/28/17
15:05
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

SIEGY

Siemens

$70.08

-0.19 (-0.27%)

, BDRBF

Bombardier

$1.83

-0.0236 (-1.27%)

15:02
06/28/17
06/28
15:02
06/28/17
15:02
Periodicals
Breaking Periodicals news story on Siemens, Bombardier »

Siemens, Bombardier…

SIEGY

Siemens

$70.08

-0.19 (-0.27%)

BDRBF

Bombardier

$1.83

-0.0236 (-1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

T

AT&T

$37.89

0.186 (0.49%)

15:00
06/28/17
06/28
15:00
06/28/17
15:00
Options
AT&T attracts downside put buyers »

AT&T attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POT

Potash

$16.34

-0.015 (-0.09%)

14:55
06/28/17
06/28
14:55
06/28/17
14:55
Options
Potash put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARA

Cara Therapeutics

$26.42

1.01 (3.97%)

, NKTR

Nektar

$18.82

-0.915 (-4.64%)

14:46
06/28/17
06/28
14:46
06/28/17
14:46
Hot Stocks
Before the Move: Watch Cara Therapeutics into osteoarthritis pain results »

Cara Therapeutics (CARA)…

CARA

Cara Therapeutics

$26.42

1.01 (3.97%)

NKTR

Nektar

$18.82

-0.915 (-4.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 06

    Jul

NRG

NRG Energy

$17.41

0.2001 (1.16%)

14:45
06/28/17
06/28
14:45
06/28/17
14:45
Options
NRG Energy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDEN

Golden Entertainment

$20.36

-0.37 (-1.78%)

14:43
06/28/17
06/28
14:43
06/28/17
14:43
Hot Stocks
Golden Entertainment announces approval for Illinois gaming terminal license »

Golden Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

Labarge

$54.33

-0.085 (-0.16%)

14:30
06/28/17
06/28
14:30
06/28/17
14:30
Options
6X average daily volume in L Brands driven by a three-way spread »

6X average daily volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENX

Fenix Parts

$1.57

0.08 (5.37%)

14:29
06/28/17
06/28
14:29
06/28/17
14:29
Hot Stocks
Fenix Parts plunges after Nasdaq delisting notice »

Shares of microcap Fenix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HL

Hecla Mining

$5.25

0.075 (1.45%)

14:28
06/28/17
06/28
14:28
06/28/17
14:28
Hot Stocks
Breaking Hot Stocks news story on Hecla Mining »

Hecla Mining trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMPH

KemPharm

$3.45

0.05 (1.47%)

14:25
06/28/17
06/28
14:25
06/28/17
14:25
Conference/Events
KemPharm to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

HL

Hecla Mining

$5.25

0.075 (1.45%)

14:24
06/28/17
06/28
14:24
06/28/17
14:24
Earnings
Hecla Mining sees Q2 revenue of $127M-$137M, consensus $145.85M »

Hecla Mining announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HL

Hecla Mining

$5.25

0.075 (1.45%)

14:21
06/28/17
06/28
14:21
06/28/17
14:21
Hot Stocks
Hecla Mining to offer $500M of senior notes »

Hecla Mining announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVA

Sinovac Biotech

$6.34

-0.07 (-1.09%)

14:20
06/28/17
06/28
14:20
06/28/17
14:20
Hot Stocks
Sinobioway Consortium confirms Sinovac Biotech offer raised to $8 per share »

Shandong Sinobioway…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
06/28/17
06/28
14:17
06/28/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
06/28/17
06/28
14:16
06/28/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QQQ

PowerShares QQQ Trust

$138.03

-2.55 (-1.81%)

14:10
06/28/17
06/28
14:10
06/28/17
14:10
Options
Defensive option play in the PowerShares QQQ »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGX

Argan

$62.40

0.9 (1.46%)

14:08
06/28/17
06/28
14:08
06/28/17
14:08
Initiation
Argan initiated  »

Argan initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HL

Hecla Mining

$5.24

0.07 (1.35%)

14:05
06/28/17
06/28
14:05
06/28/17
14:05
Hot Stocks
Breaking Hot Stocks news story on Hecla Mining »

Hecla Mining trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
06/28/17
06/28
14:05
06/28/17
14:05
General news
U.S. equities are extending their bull run »

U.S. equities are…

14:00
06/28/17
06/28
14:00
06/28/17
14:00
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

13:58
06/28/17
06/28
13:58
06/28/17
13:58
General news
Averages, internals remain strong in afternoon trading »

Stocks remain sharply…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.